199 related articles for article (PubMed ID: 19890398)
1. Oncogenic RAS enables DNA damage- and p53-dependent differentiation of acute myeloid leukemia cells in response to chemotherapy.
Meyer M; Rübsamen D; Slany R; Illmer T; Stabla K; Roth P; Stiewe T; Eilers M; Neubauer A
PLoS One; 2009 Nov; 4(11):e7768. PubMed ID: 19890398
[TBL] [Abstract][Full Text] [Related]
2. Oncogenic NRAS Primes Primary Acute Myeloid Leukemia Cells for Differentiation.
Brendel C; Teichler S; Millahn A; Stiewe T; Krause M; Stabla K; Ross P; Huynh M; Illmer T; Mernberger M; Barckhausen C; Neubauer A
PLoS One; 2015; 10(4):e0123181. PubMed ID: 25901794
[TBL] [Abstract][Full Text] [Related]
3. Prenylation-dependent Ras inhibition by pamidronate inhibits pediatric acute myeloid leukemia stem and differentiated cell growth and survival.
Wang C; Liu X; He R; Li J; Pan R
Biochem Biophys Res Commun; 2019 Sep; 517(3):439-444. PubMed ID: 31376932
[TBL] [Abstract][Full Text] [Related]
4. Patients with acute myeloid leukemia and RAS mutations benefit most from postremission high-dose cytarabine: a Cancer and Leukemia Group B study.
Neubauer A; Maharry K; Mrózek K; Thiede C; Marcucci G; Paschka P; Mayer RJ; Larson RA; Liu ET; Bloomfield CD
J Clin Oncol; 2008 Oct; 26(28):4603-9. PubMed ID: 18559876
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of MN1 confers resistance to chemotherapy, accelerates leukemia onset, and suppresses p53 and Bim induction.
Pardee TS
PLoS One; 2012; 7(8):e43185. PubMed ID: 22905229
[TBL] [Abstract][Full Text] [Related]
6. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
7. Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.
Klein K; Kaspers G; Harrison CJ; Beverloo HB; Reedijk A; Bongers M; Cloos J; Pession A; Reinhardt D; Zimmerman M; Creutzig U; Dworzak M; Alonzo T; Johnston D; Hirsch B; Zapotocky M; De Moerloose B; Fynn A; Lee V; Taga T; Tawa A; Auvrignon A; Zeller B; Forestier E; Salgado C; Balwierz W; Popa A; Rubnitz J; Raimondi S; Gibson B
J Clin Oncol; 2015 Dec; 33(36):4247-58. PubMed ID: 26573082
[TBL] [Abstract][Full Text] [Related]
8. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
[TBL] [Abstract][Full Text] [Related]
9. Mutant RAS selectively promotes sensitivity of myeloid leukemia cells to apoptosis by a protein kinase C-dependent process.
Gallagher AP; Burnett AK; Bowen DT; Darley RL
Cancer Res; 1998 May; 58(9):2029-35. PubMed ID: 9581849
[TBL] [Abstract][Full Text] [Related]
10. High-dose cytarabine in induction treatment improves the outcome of adult patients younger than age 46 years with acute myeloid leukemia: results of the EORTC-GIMEMA AML-12 trial.
Willemze R; Suciu S; Meloni G; Labar B; Marie JP; Halkes CJ; Muus P; Mistrik M; Amadori S; Specchia G; Fabbiano F; Nobile F; Sborgia M; Camera A; Selleslag DL; Lefrère F; Magro D; Sica S; Cantore N; Beksac M; Berneman Z; Thomas X; Melillo L; Guimaraes JE; Leoni P; Luppi M; Mitra ME; Bron D; Fillet G; Marijt EW; Venditti A; Hagemeijer A; Mancini M; Jansen J; Cilloni D; Meert L; Fazi P; Vignetti M; Trisolini SM; Mandelli F; de Witte T
J Clin Oncol; 2014 Jan; 32(3):219-28. PubMed ID: 24297940
[TBL] [Abstract][Full Text] [Related]
11. A Screening of Antineoplastic Drugs for Acute Myeloid Leukemia Reveals Contrasting Immunogenic Effects of Etoposide and Fludarabine.
Ocadlikova D; Iannarone C; Redavid AR; Cavo M; Curti A
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32948017
[TBL] [Abstract][Full Text] [Related]
12. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
13. Oncogenic ras and p53 cooperate to induce cellular senescence.
Ferbeyre G; de Stanchina E; Lin AW; Querido E; McCurrach ME; Hannon GJ; Lowe SW
Mol Cell Biol; 2002 May; 22(10):3497-508. PubMed ID: 11971980
[TBL] [Abstract][Full Text] [Related]
14. Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice.
Bilardi RA; Anstee NS; Glaser SP; Robati M; Vandenberg CJ; Cory S
Cell Death Dis; 2016 Sep; 7(9):e2351. PubMed ID: 27584789
[TBL] [Abstract][Full Text] [Related]
15. Synergistic effects of troglitazone in combination with cytotoxic agents in acute myelogenous leukaemia cells.
Gu C; Ye T; Wells RA
Leuk Res; 2006 Nov; 30(11):1447-51. PubMed ID: 16704876
[TBL] [Abstract][Full Text] [Related]
16. Mutated and non-mutated TP53 as targets in the treatment of leukaemia.
Nahi H; Selivanova G; Lehmann S; Möllgård L; Bengtzen S; Concha H; Svensson A; Wiman KG; Merup M; Paul C
Br J Haematol; 2008 May; 141(4):445-53. PubMed ID: 18341636
[TBL] [Abstract][Full Text] [Related]
17. Activation of the RAS pathway is predictive for a chemosensitive phenotype of acute myelogenous leukemia blasts.
Illmer T; Thiede C; Fredersdorf A; Stadler S; Neubauer A; Ehninger G; Schaich M
Clin Cancer Res; 2005 May; 11(9):3217-24. PubMed ID: 15867216
[TBL] [Abstract][Full Text] [Related]
18. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice.
Anstee NS; Bilardi RA; Ng AP; Xu Z; Robati M; Vandenberg CJ; Cory S
Cell Death Differ; 2019 Jul; 26(7):1316-1331. PubMed ID: 30470795
[TBL] [Abstract][Full Text] [Related]
19. Sensitivity and gene expression profile of fresh human acute myeloid leukemia cells exposed ex vivo to AS602868.
Jordheim LP; Plesa A; Dreano M; Cros-Perrial E; Keime C; Herveau S; Demangel D; Vendrell JA; Dumontet C
Cancer Chemother Pharmacol; 2011 Jul; 68(1):97-105. PubMed ID: 20844879
[TBL] [Abstract][Full Text] [Related]
20. Deciphering the Therapeutic Resistance in Acute Myeloid Leukemia.
Gurnari C; Pagliuca S; Visconte V
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
